Literature DB >> 872498

Elimination of furosemide in healthy subjects and in those with renal failure.

B Beermann, E Dalén, B Lindström.   

Abstract

Furosemide was administered intravenously to 5 healthy volunteers and 15 patients with various degrees of renal failure. Two patients were given the drug orally. The plasma half-life of furosemide averaged 0.79 hr in the healthy subjects. Although most patients with kidney disease had a prolonged half-life (t1/2), up to 24.58 hr, some with advanced renal failure had an almost normal t1/2. The plasma clearance of furosemide, which in the normal subjects averaged 194 ml/min, decreased proportionally with decreasing creatinine clearance, as did the renal clearance, which in the healthy subjects averaged 95 ml/min. There was no correlation between kidney function and the apparent volume of distribution or of nonrenal clearance. One patient was given 35S-labeled furosemide intravenously. Although the furosemide plasma t1/2 was essentially normal, the elimination rate of metabolites was decreased. Unlike that of healthy subjects, the main route of excretion of label was in the feces.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872498     DOI: 10.1002/cpt197722170

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  Diuretic effect and disposition of furosemide in cystic fibrosis.

Authors:  J Prandota; I J Smith; B C Hilman; J T Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of frusemide.

Authors:  R E Cutler; A D Blair
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

4.  Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension.

Authors:  F Andreasen; O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

Review 5.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

Review 6.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

7.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

8.  Furosemide disposition in patients on CAPD.

Authors:  U Martin; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  High doses of furosemide in children with acute renal failure. A preliminary retrospective study.

Authors:  J Prandota
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

10.  Determinants of the diuretic response to furosemide in infants with congestive heart failure.

Authors:  T P Green; B L Mirkin
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.